12月5日 - ** 药物开发商Praxis Precision Medicines PRAX.O股价盘前上涨31%至249.27美元
** 周四晚些时候， (link) 称美国 FDA 已同意其震颤药物 ulixacaltamide 的 NDA 申请。
** NDA 是 "新药申请 "的缩写
** 该公司还报告了其罕见癫痫治疗药物 relutrigine 的积极中期结果
** 初步调查显示，销售峰值可能超过 25 亿美元，未来将出现重要的催化剂，包括 NDA 获得批准和可能在 2026 年获得批准"--Jefferies
** 公司的 ulixacaltamide 对引起不自主颤抖的本质性震颤有显著疗效
** 截至上一交易日收盘，股价年累计上涨约 147
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.